Candel Therapeutics (NASDAQ: CADL) insider transactions
In the twelve months to 10 November 2026, executives and directors of Candel Therapeutics reported 5 open-market sales of 317,692 shares ($3.6m) and 1 open-market purchase of 550,458 shares ($3.0m), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 11 September 2026 | Tak Paul Peter | Chief Executive Officer | Open-market sale | −59,379 | $10.46 | 113,321 | Form 4 |
| 10 September 2026 | Tak Paul Peter | Chief Executive Officer | Option exercise | +125,000 | $1.55 | 393,566 | Form 4 |
| 10 September 2026 | Tak Paul Peter | Chief Executive Officer | Open-market sale | −220,866 | $11.50 | 172,700 | Form 4 |
| 17 August 2026 | Tyagarajan Seshu | Chief Technology Officer | Open-market sale | −7,000 | $12.00 | 76,865 | Form 4 |
| 29 June 2026 | Barone Francesca | Chief Scientific Officer | Open-market sale | −23,447 | $10.06 | 77,362 | Form 4 |
| 29 June 2026 | Tyagarajan Seshu | Chief Technology Officer | Open-market sale | −7,000 | $10.02 | 83,865 | Form 4 |
| 23 February 2026 | Manning Paul B | Director | Open-market purchase | +550,458 | $5.45 | 2,763,527 | Form 4 |
| 28 July 2025 | Nichols William Garrett | Chief Medical Officer | Option exercise | +937 | $1.29 | 53,430 | Form 4 |
| 28 July 2025 | Nichols William Garrett | Chief Medical Officer | Open-market sale | −937 | $6.98 | 52,493 | Form 4 |
| 30 June 2025 | Nichols William Garrett | Chief Medical Officer | Option exercise | +781 | $1.29 | 53,274 | Form 4 |
| 30 June 2025 | Nichols William Garrett | Chief Medical Officer | Open-market sale | −781 | $5.04 | 52,493 | Form 4 |
| 25 June 2025 | Papa Joseph C | Director | Grant or award | +64,239 | $4.67 | 64,239 | Form 4 |
| 25 June 2025 | Nabel Gary J. | Director | Grant or award | +5,353 | $4.67 | 5,353 | Form 4 |
| 25 June 2025 | Schoch Charles | Chief Financial Officer | Grant or award | +5,353 | $4.67 | 43,391 | Form 4 |
| 25 June 2025 | Barone Francesca | Chief Scientific Officer | Grant or award | +4,282 | $4.67 | 100,809 | Form 4 |
| 25 June 2025 | Loggia Nicoletta | Director | Grant or award | +2,141 | $4.67 | 2,141 | Form 4 |
| 25 June 2025 | Martell Christopher | Director | Grant or award | +111,349 | $4.67 | 111,349 | Form 4 |
| 25 June 2025 | Manning Paul B | Director | Grant or award | +1,070,663 | $4.67 | 2,213,069 | Form 4 |
| 25 June 2025 | Tak Paul Peter | Chief Executive Officer | Grant or award | +42,826 | $4.67 | 268,566 | Form 4 |
| 25 June 2025 | Tyagarajan Seshu | Chief Technology Officer | Grant or award | +5,353 | $4.67 | 90,865 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Candel Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.